Global Phase 3 Trial Will Test BAN2401 in Early-stage Asymptomatic Alzheimer’s

Global Phase 3 Trial Will Test BAN2401 in Early-stage Asymptomatic Alzheimer’s
BAN2401, an experimental treatment for Alzheimer’s disease (AD), will be tested in the new global AHEAD 3-45 clinical trial, its developers have announced. The Phase 3 study — to be conducted in the U.S., Canada, Japan, Australia, Singapore, and Europe — will test the therapy in people who are in the early stage of the neurological disorder and do not yet show symptoms. The trial was initiated by Eisai in collaboration with Biogen and the Alzheimer’s Clinical Trials Consortium (ACTC). The ACTC is a network of clinical sites across the U.S., established by the National Institute on Aging to accelerate testing of potential treatments for Alzheimer’s. AHEAD 3-45 (NCT04468659) will evaluate the therapeut
Subscribe or to access all post and page content.